SynthesisDrugs2015
Pemphigus vulgaris: an evidence-based treatment update.
Synthesis in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.JAMA dermatology · 2020Trial
- Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.Frontiers in immunology · 2019Trial
- Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Thiopurine Methyltransferase Levels and Azathioprine Outcomes in Thai Patients with Cutaneous Autoimmune Diseases.Clinical, cosmetic and investigational dermatology · 2026Article
- Article
- Beyond the Surface: A Clinical Insight Into a 60-Year-Old Male With Pemphigus vulgaris.Cureus · 2024Article
- Factors Associated with Candidiasis in Pemphigus Vulgaris Patients: Results from a Retrospective Study in Two Second-Care Level Hospitals in Mexico.Tropical medicine and infectious disease · 2023Article
- Pemphigus vulgaris in a neonate born to a mother with pemphigus vulgaris: A case report.Clinical case reports · 2023Article
- Informed consent and biological agents in rheumatology and internal medicine.European journal of clinical investigation · 2022Review
- IgGBiomedicines · 2022Article
- Successful management of feline pemphigus foliaceus with pentoxifylline and topical hydrocortisone aceponate.Veterinary medicine and science · 2022Article
- Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability.Patient preference and adherence · 2022Review
- Management of Pemphigus in COVID-19 Pandemic Era; a Review Article.Archives of academic emergency medicine · 2020Review
- Pemphigus vulgaris.Anais brasileiros de dermatologia · 2019Article
- Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Article
- Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center.Frontiers in medicine · 2019Article
- Pemphigus vegetans with isolated involvement of the nose and chest: rare variant of pemphigus vulgaris.Anais brasileiros de dermatologia · 2019Article
- Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.Clinical reviews in allergy & immunology · 2018Review
- Emerging treatment options for the management of pemphigus vulgaris.Therapeutics and clinical risk management · 2018Review
- Quality of systematic reviews on the treatment of vesiculobullous skin diseases. A meta-epidemiological study.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile a variety of intervention options have been described for pemphigus vulgaris, the optimal treatment strategy has not been established.
objectivesThe objective of this systematic review is to assess the literature on the efficacy and safety of interventions for the treatment of pemphigus vulgaris. DATA SOURCES: Five electronic databases were searched, including The Cochrane Skin Group's Specialized Register, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE and Latin American and Caribbean Health science Information database (LILACS). Five trial registers as well as reference lists of included RCTs were also searched. STUDY ELIGIBILITY CRITERIA: Any published randomised controlled trial (RCT) on intervention for pemphigus vulgaris was included, provided the diagnosis of pemphigus vulgaris was confirmed with appropriate clinical features, histopathology and immunofluorescence studies. Studies which included forms of pemphigus other than pemphigus vulgaris were excluded.
interventionsAltogether 18 RCTs were identified including 16 distinct interventions. STUDY APPRAISAL AND SYNTHESIS
methodsIncluded studies were assessed for patient selection, methods of randomisation, blinding, follow-up and selective reporting.
resultsCurrent evidence is incomplete and inconclusive. The interventions which appear promising, but will require further evaluation include adjuvant mycophenolate mofetil (MMF), azathioprine, intravenous immunoglobulins (IVIG), sulfasalazine and pentoxifylline, infliximab, epidermal growth factor and pimecrolimus. Interventions with inconclusive evidence include high (120-180 mg) versus low (45-60 mg) prednisone dosage, pulsed dexamethasone, cyclophosphamide, dexamethasone-cyclophosphamide pulse therapy (DCP), cyclosporine, dapsone, etanercept, acyclovir and tacrolimus. LIMITATIONS: Our review is limited by the small number of high-quality RCTs and variety of outcome measures, precluding the performing of a meta-analysis. CONCLUSIONS AND IMPLICATIONS OF KEY
findingsThe optimal treatment strategy for pemphigus vulgaris remains unclear. Higher quality RCTs are required in the future to re-evaluate many interventions and to explore other unstudied interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.